MECHANISMS OF SIGNAL TRANSDUCTION
Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6*

https://doi.org/10.1074/jbc.M103747200Get rights and content
Under a Creative Commons license
open access

The movements of transmembrane segments (TMs) 3 and 6 at the cytoplasmic side of the membrane play an important role in the activation of G-protein-coupled receptors. Here we provide evidence for the existence of an ionic lock that constrains the relative mobility of the cytoplasmic ends of TM3 and TM6 in the inactive state of the β2-adrenergic receptor. We propose that the highly conserved Arg-1313.50 at the cytoplasmic end of TM3 interacts both with the adjacent Asp-1303.49 and with Glu-2686.30 at the cytoplasmic end of TM6. Such a network of ionic interactions has now been directly supported by the high-resolution structure of the inactive state of rhodopsin. We hypothesized that the network of interactions would serve to constrain the receptor in the inactive state, and the release of this ionic lock could be a key step in receptor activation. To test this hypothesis, we made charge-neutralizing mutations of Glu-2686.30 and of Asp-1303.49 in the β2-adrenergic receptor. Alone and in combination, we observed a significant increase in basal and pindolol-stimulated cAMP accumulation in COS-7 cells transiently transfected with the mutant receptors. Moreover, based on the increased accessibility of Cys-2856.47 in TM6, we provide evidence for a conformational rearrangement of TM6 that is highly correlated with the extent of constitutive activity of the different mutants. The present experimental data together with the recent high-resolution structure of rhodopsin suggest that ionic interactions between Asp/Glu3.49, Arg3.50, and Glu6.30may constitute a common switch governing the activation of many rhodopsin-like G-protein-coupled receptors.

Cited by (0)

Published, JBC Papers in Press, May 25, 2001, DOI 10.1074/jbc.M103747200

*

This work was supported in part by National Institute of Mental Health Grants MH57324 and MH54137, the G. Harold and Leila Y. Mathers Charitable Trust, and the Lebovitz Trust (to J. A. J.) and the Danish Natural Science Research Council, the Danish Cancer Society, the Danish Heart Foundation, and the NOVO Nordic Foundation (to U. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

These authors contributed equally to this work.

Present address: Maxygen, Agern Allé 1, DK-2970 Hørsholm, Denmark.

§§

Recipient of an Ole Romer Associate Research Professorship from the Danish Natural Science Research Council.

¶¶

To whom correspondence may be addressed. Tel.: 45-3532-7548; Fax: 45-3532-7555; E-mail: [email protected].

166

To whom correspondence may be addressed: Center for Molecular Recognition and the Depts. of Psychiatry and Pharmacology, Columbia University College of Physicians and Surgeons, 630 W. 168th St., P&S 11-401, New York, NY 10032. Tel.: 212-305-7308; Fax: 212-305-5594; E-mail: [email protected].